Evidence map›Paper›PMID 41496633›Full record

ReviewBiomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia2026

Mini review on the laboratory diagnosis of amyloidosis: An overview of methods, applications, and trends in analytical approaches.

Ivana Olivkova, Pavel Sistik, Katerina Kratka, Pavlina Kusnierova, Zdenek Svagera, Jan Jurica, Petr Handlos, Klara Handlosova, David Stejskal

Abstract readReview
PubMed Publisher
In one paragraph

Review in Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ivana OlivkovaInstitute of Laboratory Medicine, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
Pavel SistikInstitute of Laboratory Medicine, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
Katerina KratkaInstitute of Laboratory Medicine, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
Pavlina KusnierovaInstitute of Laboratory Medicine, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
Zdenek SvageraInstitute of Laboratory Medicine, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
Jan JuricaDepartment of Pharmacology, Faculty of Medicine and Department of Pharmacology and toxicology, Faculty of Pharmacy, Masaryk University, Brno, Czech Republic.
Petr HandlosDepartment of Forensic Medicine, University Hospital Ostrava, Ostrava, Czech Republic.
Klara HandlosovaDepartment of Forensic Medicine, University Hospital Ostrava, Ostrava, Czech Republic.
David StejskalInstitute of Laboratory Medicine, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Amyloidosis represents a clinically and molecularly heterogeneous group of serious, potentially life-threatening disorders characterized by the extracellular deposition of insoluble amyloid fibrils derived from misfolded precursor proteins. These deposits disrupt tissue architecture and function, often affecting vital organs such as the heart and kidneys. Accurate diagnosis and subtyping of amyloidosis are essential for effective clinical management and personalized therapeutic interventions. This review provides an integrated overview of modern approaches to the laboratory diagnosis of amyloidosis, divided into three main areas: (1) histological and immunological methods (including Congo red staining, immunohistochemistry, immunofluorescence, and immunoelectron microscopy) for the initial detection and characterization of amyloid deposition, (2) electrophoretic techniques (capillary electrophoresis, isoelectric focusing, immunofixation electrophoresis) used primarily for the analysis of amyloid-associated proteins in serum and urine, and (3) mass spectrometry-based proteomic analyses that have significantly improved subtype specificity and clinical decision-making. By emphasizing the complementary roles of these techniques, the review aims to support timely, accurate, and subtype-specific diagnosis, ultimately improving clinical outcomes and treatment strategies for patients affected by amyloidosis.

Indexed as

AmyloidosisAmyloidBiomarkersHumansImmunohistochemistryMass SpectrometryProteomicsAmyloidBiomarkersamyloidosisbiomarkersdiagnosticslaboratorymass spectrometryproteomics

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.